EVQLV Podcast: Recent Episodes
Daniel Gigante
EVQLV develops artificial intelligence, engineered with life science data and biological knowledge, to accelerate the speed at which biologic therapies reach patients. Our expertise in machine learning, computational biology, software engineering, and preclinical/clinical development strengthens our mission of transforming how healing reaches those in need.
EVQLV's podcast covers our work at EVQLV, new and interesting events at the intersection of AI and Life Science and more.
EVQLV CEO, Andrew Satz, joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia to discuss his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.).
More from Dr Sophia Ononye-Onyia: https://sophiaconsultingfirm.com/?blog=y
More from EVQLV: https://evqlv.com/
EVQLV's CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more. Give it a listen. Timestamps below.
- Andrew's entrepreneurial journey - 0:46
- Insight into what EVQLV does - 6:05
- Lessons learned in Andrew's career - 14:17
- Was this something Andrew always knew he wanted to do? - 20:27
- What are some of the challenges facing artificial intelligence in healthcare - 23:28
- Discussion on leadership - 30:21
- Benefits of AI and the responsibility facing those developing AI - 34:08
- Career highlights - 37:19
- The future of medicine and telemedicine with respect to AI - 41:05
- Effects of AI on privacy - 45:04
- advise for entrepreneurs - 49:03
- Andrew's legacy - 55:56
EVQLV's very own Andrew Satz (CEO and CO-Founder) was a guest on the M2 Techcast of MITechNews.com with Mike Brennan and Matt Roush. He discussed our work on coronavirus, what is and isn't artificial intelligence, the application of AI, and our mission at EVQLV. Give it a listen.
This is part 2 of our event with BioIDEA: Biotech vs COVID-19
BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
Our panelists included Elena Diez Cecilia, Director of Business Development and R&D Strategy at A2A Pharmaceuticals, Ed Painter, Chairman and CIO of A2A Pharmaceuticals; Peter Leonardi, CEO and Founder of OmniCyte; and our very own Andrew Satz, CEO and Co-Founder of EVQLV.
More from BioIDEA: https://bioidea.co/
More from A2A Pharmaceuticals: https://a2apharma.com/
More form OmniCyte: https://omnicyte.com/
More from EVQLV: https://evqlv.com/
This is part 1 of our event with BioIDEA: Biotech vs COVID-19
BioIDEA and EVQLV hosted a panel discussion and Q&A on the role of emerging technologies in the fight against COVID-19.
Our panelists included Elena Diez Cecilia, Director of Business Development and R&D Strategy at A2A Pharmaceuticals, Ed Painter, Chairman and CIO of A2A Pharmaceuticals; Peter Leonardi, CEO and Founder of OmniCyte; and our very own Andrew Satz, CEO and Co-Founder of EVQLV.
More from BioIDEA: bioidea.co/
More from A2A Pharmaceuticals: a2apharma.com/
More form OmniCyte: omnicyte.com/
More from EVQLV: evqlv.com/
This is a clip from our CEO's recent speech at the Flatiron School. In short, he covers what we do at EVQLV (we discovery novel biologics using AI) and how we do it (an evolutionary algorithm with applied external pressures).
There's a lot more to it, but we felt obliged to give a taste of our "secret sauce."
For more information visit our website here: evqlv.com/
Music provided by bensound: bensound.com/
Brett Averso, CTO, and I linked up to discuss the coronavirus (SARS-CoV-2). Brett covered what exactly the coronavirus is, the threat it currently presents (attention given to relative threat with respect to the original SARS virus [SARS-CoV] and MERS [MERS-CoV]), how we can best protect ourselves and our loved ones against infection, and what EVQLV is doing to address the outbreak. Timestamps provided below.
What is the coronavirus? [0:08]
What type of threat does the coronavirus present? [1:10]
How can we protects ourselves and our loved ones against coronavirus infection? [3:49]
What are we doing at EVQLV to address the outbreak [5:56]
View data referenced by Brett here: github.com/HopkinsIDD/ncov_incubation
Additional Relevant data: jamanetwork.com/journals/jama/ful…l&utm_term=022420
CDC guidelines: www.cdc.gov/coronavirus/2019-ncov/about/index.html
More from EVQLV here: www.evqlv.com/
Music provided by bensound: bensound.com/
How does EVQLV understand and utilize AI? AI is a term that gets thrown around constantly. However, it's often misused and/or misunderstood. Andrew Satz breaks down what it means when a company says they utilize AI, how EVQLV understands and leverages AI, and how AI may be able to make us more human. Time stamps below.
What does it mean when a company says they’re leveraging AI? [0:08]
How should it be understood when we say we’re using AI? [3:27]
What type of AI are we leveraging: [5:36]
Can AI make us MORE human?: [8:45]
For more information visit our website: www.evqlv.com/
Music: bensound.com
In this discussion, Andrew Satz, CEO and Daniel Gigante chat about the cost of pharmaceuticals. Andrew begins by detailing the major input required to not just bring a drug to market, but to protect it legislatively. He then covers how AI (read: EVQLV) can potentially reduce the cost of drug discovery.
With respect to EVQLV, Andrew feels the company can't eliminate any variables that factor into cost, but instead can mitigate the damage from specific variables.
Music: www.bensound.com/
For more information on EVQLV, check out our site here: www.evqlv.com/